Skip to main content

Advertisement

SpringerLink
Log in

Case studies in anticoagulation management

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Leong WA (2004) Anticoagulation opportunities for community pharmacists. Pharm Practice 20(11):CE1–8

    Google Scholar 

  2. Ansell J, Hollowell J, Pengo V et al (2007) Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J Thromb Thrombolysis 23(2):83–91

    Article  PubMed  Google Scholar 

  3. Ansell JE, Oertel LB and Wittkowsky AK (eds) (2003) Managing Oral Anticoagulation: Clinical & Operational Guidelines, 2nd edn. Aspen Publishers, New York, NY

  4. Ansell JE, the Anticoagulation Guidelines Task Force (1997) Consensus guidelines for coordinated outpatient oral anticoagulation therapy management. Ann Pharmacother 31:604–615

    PubMed  CAS  Google Scholar 

  5. Ansell J, Hirsh J, Poller L et al (2004) The pharmacology and management of the vitamin K antagonists: the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:204S–233S

    Article  PubMed  CAS  Google Scholar 

  6. Surgical management of the primary care dental patient on warfarin Revised March (2006) North West Medicines Information Centre, Liverpool, England. (http://www.dundee.ac.uk/tuith/Static/info/warfarin.pdf). Accessed on April 2007

  7. Salem DN, Stein PD, Al-Ahmad A et al (2004) Antithrombotic therapy in valvular heart disease—native and prosthetic: the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:457S–482S

    Article  PubMed  CAS  Google Scholar 

  8. Hirsh J, Raschke R (2004) Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:188S–203S

    Article  PubMed  CAS  Google Scholar 

  9. Douketis JD, Woods K, Crowther MA (2005) Anticoagulation management of patients undergoing elective surgery who require temporary interruption of warfarin therapy. 2nd edn. McMaster University Dept. of Medicine and St. Joseph’s Healthcare, Hamilton, Canada

    Google Scholar 

  10. Mannucci C, Douketis JD (2006) The management of patients who require temporary reversal of vitamin K antagonists for surgery: a practical guide for clinicians. Intern Emerg Med 1(2):94–95

    Article  Google Scholar 

  11. Spyropoulos AC, Turpie AG, Dunn AS et al (2006) Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost 4(6):1246–1252

    Article  PubMed  CAS  Google Scholar 

  12. Dunn A (2006) Perioperative management of oral anticoagulation: when and how to bridge. J Thromb Thrombolysis 21(1):85–89

    Article  PubMed  Google Scholar 

  13. Meurin P, Tabet JY, Weber H et al (2006) Low-molecular-weight heparin as a bridging anticoagulant early after mechanical heart valve replacement. Circulation 113(4):564–569

    Article  PubMed  CAS  Google Scholar 

  14. O’Donnell MJ, Kearon C, Johnson J et al (2007) Brief communication: preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Ann Intern Med 146(3):184–187

    PubMed  Google Scholar 

  15. Deerhake JP, Merz JC, Cooper JV et al (2007) The duration of anticoagulation bridging therapy in clinical practice may significantly exceed that observed in clinical trials. J Thromb Thrombolysis 23(2):107–13

    Article  PubMed  Google Scholar 

  16. Douketis JD, Woods K, Foster GA et al (2005) Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery. Thromb Haemost 94(3):528–531

    PubMed  CAS  Google Scholar 

  17. Leong WA (1998) Outpatient deep vein thrombosis treatment models. Pharmacotherapy 18(6 Pt 3):170S–174S

    PubMed  CAS  Google Scholar 

  18. Hulse ML (1996) Warfarin resistance: diagnosis and therapeutic alternatives. Pharmacotherapy 16(6):1009–1017

    PubMed  CAS  Google Scholar 

  19. Rost S, Fregin A, Ivaskevicius V et al (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427(6974):537–541

    Article  PubMed  CAS  Google Scholar 

  20. Yasar AS, Balbay Y, Maden O et al (2007) Early mechanical mitral valve thrombosis in a patient with warfarin resistance. J Heart Valve Dis 16(2):200–202

    PubMed  Google Scholar 

  21. Holt RJ, Freytes CO (1983) Familial warfarin resistance. Drug Intell Clin Pharm 17(4):281–283

    PubMed  CAS  Google Scholar 

  22. Alving BM, Strickler MP, Knight RD et al (1985) Hereditary warfarin resistance. investigation of a rare phenomenon. Arch Intern Med 145(3):499–501

    Article  PubMed  CAS  Google Scholar 

  23. Dager WE, Dougherty JA, Nguyen PH et al (2007) Heparin-induced thrombocytopenia: treatment options and special considerations. Pharmacotherapy 27(4):564–587

    Article  PubMed  CAS  Google Scholar 

  24. Taylor LM, Smith KM (2005) The paradox of heparin-induced thrombocytopenia: future anticoagulation. Orthopedics 28(7):651–654

    PubMed  Google Scholar 

  25. Attassi K, Hershberger E, Alam R et al (2002) Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 34(5):695–698

    Article  PubMed  Google Scholar 

  26. Waldrep TW, Skiest DJ (2002) Linezolid-induced anemia and thrombocytopenia. Pharmacotherapy 22(1):109–112

    Article  PubMed  Google Scholar 

  27. Gerson SL, Kaplan SL, Bruss JB et al (2002) Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 46(8):2723–2726

    Article  PubMed  CAS  Google Scholar 

  28. Greinacher A, Warkentin TE (2006) Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update. Thromb Res 118(2):165–176

    Article  PubMed  CAS  Google Scholar 

  29. Gruel Y, Pouplard C, Nguyen P et al (2003) Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br J Hematol 121(5):786–792

    Article  CAS  Google Scholar 

  30. Warkentin TE (2002) Heparin-induced thrombocytopenia: part 1. J Crit Illness 17(5):172–178

    Google Scholar 

  31. Spinler SA, Dager WE (2003) Overview of heparin-induced thrombocytopenia. Am J Health Syst Pharm 60:S5–S11

    PubMed  CAS  Google Scholar 

  32. Spinler SA (2003) Managing heparin-induced thrombocytopenia: preventing life- and limb-threatening thrombosis. Am J Health Syst Pharm 60:S2–S4

    PubMed  Google Scholar 

  33. Girolami B, Girolami A (2006) Heparin-induced thrombocytopenia: a review. Semin Thromb Hemost 32(8):803–809

    Article  PubMed  CAS  Google Scholar 

  34. Keeling D, Davidson S, Watson H (2006) The management of heparin-induced thrombocytopenia. Br J Haematol 133(3):259–269

    Article  PubMed  CAS  Google Scholar 

  35. Warkentin TE, Greinacher A (2004) Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3 Suppl):311S–337S

    Article  PubMed  CAS  Google Scholar 

  36. Andreescu AC, Cushman M (2000) Case studies in heparin-induced thrombocytopenia. J Thromb Thrombolysis 10(Suppl):71–76

    Article  PubMed  Google Scholar 

  37. Nagao T, Ibayashi S, Fujii K et al (1995) Treatment of warfarin-induced hair loss with ubidecarenone. Lancet 346:1104–1105

    Article  PubMed  CAS  Google Scholar 

  38. Akihama T, Nakamoto Y, Shindo T et al (1983) Protective effects of Coenzyme Q10 on the adverse reactions of anthracycline antibiotics. Gan To Kagaku Ryoho (Cancer & Chemotherapy) 10(10):2125–2129, [Article in Japanese]

    CAS  Google Scholar 

  39. Frishman WH, Brosnan BD, Grossman M et al (2002) Adverse dermatologic effects of cardiovascular drug therapy: part II. Cardiol in Rev 10(5):285–300

    Article  Google Scholar 

  40. Ahmad S (1991) Enalapril and reversible alopecia. Arch Intern Med 151(2):404

    Article  PubMed  CAS  Google Scholar 

  41. Motel PJ (1990) Captopril and alopecia: a case report and review of known cutaneous reactions in captopril use. J Am Acad Dermatol 23(1):124–125

    Article  PubMed  CAS  Google Scholar 

  42. Thiedke C (2003) Alopecia in women. Am Fam Physician 67:1007–1014, 1017–1018

    Google Scholar 

  43. Umlas J, Harken DE (1988) Warfarin-induced alopecia. Cutis 42(1):63–64

    PubMed  CAS  Google Scholar 

  44. Kaur M and Kern M (2002) Warfarin sodium induced alopecia. Pharmascript 25(7)

  45. Anon (1995) A close shave... warfarin induced alopecia. ADRB 173:655–658

  46. Wang YY, Po HL (2006) Enoxaparin-induced alopecia in patients with cerebral venous thrombosis. J Clin Pharm Ther 31(5):513–517

    Article  PubMed  Google Scholar 

  47. Sarris E, Tsele E, Bagiatoudi G et al (2003) Diffuse alopecia in a hemodialysis patient caused by a low-molecular-weight heparin, tinzaparin. Am J Kidney Dis 41(5):E15

    PubMed  Google Scholar 

  48. Qureshi GD, Reinders TP, Swint JJ et al (1981) Acquired warfarin resistance and weight-reducing diet. Arch Intern Med 141(4):507–519

    Article  PubMed  CAS  Google Scholar 

  49. Reese AM, Farnett LE, Lyons RM et al (2005) Low-dose vitamin K to augment anticoagulation control. Pharmacotherapy 25(12):1746–1751

    Article  PubMed  CAS  Google Scholar 

  50. Hartig C, Lang M, Weibert R (2007) Low-dose daily vitamin K supplement in patients anticoagulated with warfarin. Abstract presented at the anticoagulation forum 9th National Conference in Chicago, Illinois

  51. Ford SK, Misita CP, Shilliday BB et al (2007) Prospective study of supplemental vitamin K therapy in patients on oral anticoagulants with unstable international normalized ratios. J Thromb Thrombolysis 24(1):23–27, Epub 2007 Feb 24

    Article  PubMed  CAS  Google Scholar 

  52. Ford S, Moll S (2007) Supplemental vitamin K in patients on warfarin with unstable INRs. J Thromb Thrombolysis 24(1):23–27

    Article  PubMed  CAS  Google Scholar 

  53. Lim W, Crowther MA, Eikelboom JW (2006) Management of antiphospholipid antibody syndrome: a systematic review. JAMA 295(9):1050–1057

    Article  PubMed  CAS  Google Scholar 

  54. Ortel TL (2006) The antiphospholipid syndrome: what are we really measuring? How do we measure it? And how do we treat it? J Thromb Thrombolysis 21(1):79–83

    Article  PubMed  CAS  Google Scholar 

  55. Crowther MA, Wisloff F (2005) Evidence based treatment of the antiphospholipid syndrome II. Optimal anticoagulant therapy for thrombosis. Thromb Res 115(1–2):3–8

    PubMed  CAS  Google Scholar 

  56. Erkan D, Lockshin MD (2004) How much warfarin is enough in APS related thrombosis? Thromb Res 114(5–6):435–442

    Article  PubMed  CAS  Google Scholar 

  57. Erkan D, Lockshin MD (2006) Antiphospholipid syndrome. Curr Opin Rheumatol 18(3):242–248

    Article  PubMed  CAS  Google Scholar 

  58. Sucker C, Wenzel F, Zotz RB et al (2006) Monitoring oral anticoagulation may require determination of single coagulation factor activities in patients with antiphospholipid syndrome. J Rheumatol 33(9):1881–1882

    PubMed  Google Scholar 

  59. Moll S, Oertel TL (1997) Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 127(3):177–185

    PubMed  CAS  Google Scholar 

  60. Wittkowsky AK, Downing J, Blackburn J et al (2006) Warfarin-related outcomes in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic. Thromb Haemost 96(2):137–141

    PubMed  CAS  Google Scholar 

  61. Sconce E, Avery P, Wynne H et al (2007) Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 109(6):2419–2433

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Many thanks to Dr. Jack Ansell, the former chair of the Anticoagulation Forum (AF) for the past 16 years; and the AF participants who contributed 3 of these cases for discussion at the last AF Forum in May 2007.

Author information

Authors and Affiliations

  1. Burnaby Research, Box 425 at 141-6200 McKay Ave, Vancouver, BC, Canada, V5H 4M9

    Wendy A. Leong

Authors
  1. Wendy A. Leong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wendy A. Leong.

Additional information

Disclosure: Research investigator/coordinator, speaker, panelist and/or consultant for Apotex, AstraZeneca, BMS, Bayer, Leo, Pharmacia, Roche, Sanofi-Aventis, Taro and other antithrombotic manufacturers.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leong, W.A. Case studies in anticoagulation management. J Thromb Thrombolysis 25, 78–84 (2008). https://doi.org/10.1007/s11239-007-0109-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-007-0109-6

Keywords

Search

Navigation